Blood Analyzers in Wisconsin

Werfen (formerly Immucor, Inc.) is a global leader in specialized diagnostics for transfusion and transplantation medicine. The company manufactures a comprehensive portfolio of serology-based reagents, automated instruments, and molecular diagnostic products serving blood banks, transfusion services, clinical laboratories, reference laboratories, donor centers, and transplant programs worldwide. Core product lines include: (1) Transfusion diagnostics—blood typing, antibody screening and identification, platelet serology, and HLA donor screening assays; (2) Transplant diagnostics—HLA typing kits (including NanoTYPE® HLA-11 Plus), HLA and non-HLA antibody detection products, and post-transplant monitoring assays; and (3) Coagulation diagnostics for heparin-induced thrombocytopenia (HIT) and thrombotic thrombocytopenic purpura (TTP) detection. Signature automated platforms include the NEO® and NEO Iris® systems for immunohematology automation, and Echo Lumena® for antibody identification with enhanced imaging. The company acquired Omixon (Hungary) to expand HLA typing capabilities. Werfen operates globally across hospital blood banks, reference laboratories, and transplant centers, leveraging customer-centric support with field representatives who possess transfusion and transplant technical expertise. The company emphasizes regulatory compliance, quality assurance, and comprehensive technical and educational support to streamline laboratory workflows and improve patient outcomes in transfusion and transplant medicine.

Promega Corporation is a global life science reagent and instrument manufacturer specializing in assays, reagents, and detection systems for research, drug discovery, clinical diagnostics, and forensic applications. The company develops bioluminescent reporter systems (NanoLuc® Luciferase, firefly luciferase), qPCR and RT-qPCR master mixes (GoTaq® systems), cell viability and apoptosis assays (CellTiter-Glo®, Caspase-Glo®), kinase selectivity profiling platforms (NanoBRET® systems), and imaging instrumentation (GloMax® Galaxy bioluminescence imager). Primary markets include small-molecule drug discovery, cell and gene therapy development, clinical research and molecular diagnostics, human identification (forensic DNA analysis), and academia. Manufacturing and R&D operations in Madison, Wisconsin are ISO 9001 (Quality Management Systems) and ISO 14001:2015 (Environmental Management Systems) certified. Products are manufactured under stringent quality control standards suitable for regulated clinical and diagnostic applications. Technical support and customer service resources include protocols, certificates of analysis, safety data sheets, and dedicated technical services scientists. The company serves pharmaceutical, biotech, clinical laboratory, forensic, and academic research markets globally.

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, specializing in cancer detection, diagnosis, and treatment guidance through advanced genomic testing. The company develops and delivers multi-cancer early detection tests, hereditary cancer risk assessment panels, and oncology genomic profiling solutions. Primary product lines include Cologuard (at-home colorectal cancer screening utilizing stool-based DNA testing), Oncotype DX (tissue-based genomic assays for breast, colon, and prostate cancers providing recurrence risk scores and treatment recommendations), and other specialized genomic tests. Exact Sciences operates state-of-the-art CLIA-certified laboratories and conducts rigorous clinical validation studies published in peer-reviewed journals. The company serves patients, healthcare providers, oncologists, and researchers globally, with a focus on enabling informed clinical decision-making through precision medicine. Recently acquired by Abbott, Exact Sciences maintains strong regulatory credentials including FDA clearances for its key diagnostic assays. The company emphasizes collaboration with top medical institutions, advocacy organizations, and policymakers to expand access to genomic cancer testing and improve early detection rates across diverse populations.